Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LioCyx-M for Prevention of HCC Recurrence Post-Transplant
NCT02686372Phase 1Completed
- Sponsor
- Lion TCR
- Start
- May 2018
- Primary completion
- Sep 2021
- Modality
- Gene Editing, Bone Marrow HSCs, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of liocyx-m in hepatocellular carcinoma (HCC) (2 arms), sponsored by Lion TCR. Primary endpoint: Safety of the TCR-T treatment. Started May 2018; status: completed.
02
Drugs
liocyx-m
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02686372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02686372.